MAP2K1 and neurofibromatosis: Selumetinib (miss) is known as a non‐ATP‐competitive inhibitor of MEK1/2 and, as such, has been FDA‐approved as a tumor therapy drug[68] – first for tumors associated with neurofibromatosis.